Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell therapies for the treatment of haematological malignancies, has launched a USD42m Series A financing round led by 5AM Ventures and RA Capital Management, it was reported on Friday.

Johnson & Johnson Innovation – JJDC, Incorporated, Novartis Institutes for BioMedical Research (NIBR) and Osage University Partners also participated in the round, as well as Vor co-founder, PureTech Health. The company plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukaemia towards the clinic, and to further build its pipeline to treat hematologic malignancies.

Kush Parmar, MD, PhD, managing partner at 5AM Ventures, who has joined the Vor Biopharma board of directors as executive chair, stated: "Vor's unique and patented technology platform for enabling targeted immunotherapies using engineered HSCs has the potential to disrupt the treatment landscape for hematologic malignancies. We are excited to work with Vor to drive this next chapter of growth forward."